MDT-AP-0839
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 73.56
- os_event
- false
- age_years
- 2
- sex
- M
- new_clusters
- C5
- umap1_2d
- 5.827079472
- umap2_2d
- 4.690549147
- umap1_3d
- 2.668006982
- umap2_3d
- -0.347828049
- umap3_3d
- -1.586483552
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.410
- KRAS_SIGNALING_DN+0.330
- SPERMATOGENESIS+0.250
- APICAL_SURFACE+0.200
- ESTROGEN_RESPONSE_LATE+0.090
- ALLOGRAFT_REJECTION+0.070
- BILE_ACID_METABOLISM+0.070
- OXIDATIVE_PHOSPHORYLATION+0.060
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.060
- MYOGENESIS+0.000
Top 10 suppressed
- MYC_TARGETS_V2-0.580
- UNFOLDED_PROTEIN_RESPONSE-0.510
- MYC_TARGETS_V1-0.420
- WNT_BETA_CATENIN_SIGNALING-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- MITOTIC_SPINDLE-0.390
- G2M_CHECKPOINT-0.370
- MTORC1_SIGNALING-0.350
- UV_RESPONSE_UP-0.350
- TGF_BETA_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1433088 | GTEX | — | 0.892 |
| 2 | MNG339 | — | — | 0.890 |
| 3 | TCGA-49-AARQ-01A-11R-A41B-07 | — | cohortA1 | 0.883 |
| 4 | SRR1321462 | GTEX | — | 0.880 |
| 5 | SRR1331534 | GTEX | — | 0.879 |
| 6 | SRR1355262 | GTEX | — | 0.877 |
| 7 | SRR1332048 | GTEX | — | 0.876 |
| 8 | SRR1473422 | GTEX | — | 0.869 |
| 9 | SRR1360150 | GTEX | — | 0.869 |
| 10 | MNG506 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.410 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |